Extended-spectrum β-lactamases (ESBL) 성질을 가진 세균에 의한 요로감염 = Extended-spectrum β-lactamases Producing Bacteria in Urinary Tract Infection

다국어 초록 (Multilingual Abstract)

Multi-drug-resistant Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBLs) have emerged in the communities and hospitals. Because β-lactamases are bacterial enzymes that hydrolyze β-lactamring in antibiotics, cephalosporins are not usually effective. Most ESBLs can be divided into three groups: TEM, SHV, and CTX-M. Recently, AmpC β-lactamase is included in this category. The clinical significance of ESBL bacteria is well known. Initially, ESBL bacteria exhibitmulti-drug resistance, such as co-trimoxazole, tetracycline, gentamicin, and fluroquinolone, as well as broad-spectrum cephalosporins. In addition, they can be transmitted to other places andother people. Moreover, inappropriate empirical therapy to urinary tract infection secondary to ESBL bacteria is usually associated with higher mortality. For these reasons, gram-negative pathogens that produce ESBLs remain an important cause oftherapy failure with newly developed cephalosporins, and incur serious complications and have consequences in infection control in the community. Consequently, it is an urgent issue to understand the characteristics of ESBL bacteria to minimize their spread and to treat ESBL associated urinary tract infection. We herein review the clinical significances of ESBL bacteria in urinary tract infection.

참고문헌 (Reference)

1 "http://en.wikipedia.org/wiki/Penicillin"

2 "http://en.wikipedia.org/wiki/Beta-lactamase"

3 Adam HJ, "The Canadian Antimicrobial Resistance Alliance (CARA). Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study" 69 : 307-313, 2011

4 Robin F, "TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5)" 49 : 4443-4447, 2005

5 Livermore DM, "Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae" 37 : 405-409, 2011

6 Khawcharoenporn T, "Risk factors for community-associated methicillin- resistant Staphylococcus aureus cellulitis-and the value of recognition" 69 : 232-236, 2010

7 Pfeifer Y, "Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens" 300 : 371-379, 2010

8 Pfeifer Y, "Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens" 300 : 371-379, 2010

9 Rooney PJ, "Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)- producing ciprofloxacin-resistant Escherichia coli" 64 : 635-641, 2009

10 Stefani S, "Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance" 14 (14): 19-22, 2010

11 Ben Ami R, "Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital" 42 : 925-934, 2006

12 Pitout JD, "Infections with extended-spectrum beta- lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices" 70 : 313-333, 2010

13 Cantón R, "IRT and CMT beta-lactamases and inhibitor resistance" 14 (14): 53-62, 2008

14 이학민, "Frequency of Extended-spectrum b-lactamase (ESBL) and AmpC b-lactamase Genes in Escherichia coli and Klebsiella pneumoniae over a Three-year Period in a University Hospital in Korea" 대한진단검사의학회 30 (30): 616-623, 2010

15 Paterson DL, "Extended-spectrum- lactamases: a clinical update" 18 : 657-686, 2005

16 Sohei Harada, "Extended-spectrum β-Lactamases: Implications for the Clinical Laboratory and Therapy" 대한진단검사의학회 28 (28): 401-412, 2008

17 Pitout JD, "Extended-spectrum beta-lactamase- producing Enterobacteriaceae: an emerging public-health concern" 8 : 159-166, 2008

18 Yang K, "Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms" 41 : 1427-1435, 2007

19 Ehlers MM, "Detection of blaSHV, blaTEM and blaCTX-M antibiotic resistance genes in randomly selected bacterial pathogens from the Steve Biko Academic Hospital" 56 : 191-196, 2009

20 Livermore DM, "Defining an extended-spectrum beta- lactamase" 14 (14): 3-10, 2008

21 Schwaber MJ, "Containment of a Countrywide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention" 11 : 2011

22 김성한, "Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase" OXFORD UNIV PRESS 54 : 1130-1133, 200412

23 Senol S, "Carbapenem versus fosfomycin tromethanol in thetreatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection" 22 : 355-357, 2010

24 Jackson RW, "Bacterial pathogen evolution: breaking news" 27 : 32-40, 2011

25 Chan VL, "Bacterial genomes and infectious diseases" 54 : 1-7, 2003

26 Gudiol C, "Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes" 66 : 657-663, 2011

27 Gupta V, "An update on newer beta-lactamases" 126 : 417-427, 2007

28 Jacoby GA, "AmpC beta-lactamases" 22 : 161-182, 2009

29 Bush K, "A functional classification scheme for beta-lactamases and its correlation with molecular structure" 39 : 1211-1233, 1995